CRVS - Corvus Pharmaceuticals: More Than A CD73 Sympathy Play

• Shares rose by 135% on Friday alone, but as of Wednesday have still lost half their value since 2017. Additionally, current enterprise value is still around $260 million.
• ESMO data release for AstraZeneca's COAST study in lung cancer has potentially validated CD73 drug class, of which Corvus possesses a differentiated candidate.
• Corvus' management team is highly experienced (ex Pharmacyclics), and for mupadolimab are striving to prove their hypothesis in viral associated cancers with wide-reaching implications.
• Not to be forgotten, there are other angles to the story including COVID optionality and ITK inhibitor CPI-818 in T cell lymphomas (big opportunity in China) & autoimmune diseases.
• Corvus is a buy. Key risks include disappointing clinical data (own or peer), competition, delays (pandemic related) and dilution.

For further details see: